JPMorgan analyst Anupam Rama placed shares of Ultragenyx (RARE) on “Positive Catalyst Watch” ahead of the company’s ORBIT and COSMIC study updates. The firm has confidence in setrusumab’s clinical success and keeps an Overweight rating on the shares with a $125 price target At current share levels, JPMorgan sees a “very positive” reward/risk profile heading into the updates with more win scenarios than downside scenarios.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx appoints Eric Olson Chief Business Officer
- Ultragenyx Pharmaceutical: Promising Phase 3 Results for DTX401 Reinforce Buy Rating
- Ultragenyx Pharmaceuticals: Strong Buy Rating Backed by Promising Osteogenesis Imperfecta Program and Strategic Developments
- Ultragenyx’s DTX401: Promising Phase 3 Results and Commercial Viability Support Buy Rating
- Buy Rating Affirmed for Ultragenyx Pharmaceutical: Promising Phase III Results of DTX401 Gene Therapy